Clinical Research Directory
Browse clinical research sites, groups, and studies.
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
Sponsor: Benjamin Viglianti
Summary
This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2021-11-01
Completion Date
2026-12
Last Updated
2025-12-05
Healthy Volunteers
Yes
Conditions
Interventions
Dexamethasone (Group 2)
Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
Cosyntropin (Group 3)
Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
PET/CT Scan with FNP-59
FNP-59, a radiotracer, is administered for PET/CT scans.
Locations (2)
University of Michigan
Ann Arbor, Michigan, United States
BAMF Health, Inc.
Grand Rapids, Michigan, United States